PGE1 inhibits the expression of PAI-1 mRNA induced by TNF-α in human mesangial cells

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 7, 2005, Pages 365-371

  Kishida, M ^a   Urakaze, Masaharu ^a   Takata, M ^a   Nobata, Y ^a   Yamamoto, N ^a   Temaru, R ^a   Sato, A ^a   Yamazaki, K ^a   Nakamura, N ^b   Kobayashi, M ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Human mesangial cells; PAI 1; PGE1; SAPK JNK; TNF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN E1; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME PHOSPHORYLATION; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; INCUBATION TIME; MESANGIUM CELL; PRIORITY JOURNAL;

ALPROSTADIL; BLOTTING, NORTHERN; BLOTTING, WESTERN; CYCLIC AMP; DIABETIC NEPHROPATHIES; DRUG INTERACTIONS; GLOMERULAR MESANGIUM; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23044481215     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865681     Document Type: Article

References (51)

1. Andreasen PA, George B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19
2. Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995; 47: 1039-1047
3. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65: 663-675
4. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
5. Dell K, Bohler T, Gaedeke J et al. Impact of PGE1 on cyclosporine A induced up-regulation of TGF-beta1, its receptors, and related matrix production in cultured mesangial cells. Cytokine 2003; 22: 189-193
6. Denu JM, Zhou G, Wu L, Zhao R, Yuvaniyama J, Saper MA, Dixon JE. The purification and characterization of a human dual-specific protein tyrosine phosphatase. J Biol Chem 1995; 270: 3796-3803
7. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994; 76: 1025-1037
8. Ding AH, Porteu F, Sanchez E, Nathan CF. Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents. J Exp Med 1990; 171: 715-727
9. Dzurik R, Spustova V, Janekova K. The prevalence of insulin resistance in kidney disease patients before the development of renal failure. Nephron 1995; 69: 281-285
10. EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1791
11. Freshney NW, Rawlinson L, Guesdon F et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 1994; 78: 1039-1049
12. Groop L, Ekstrand A, Forsblom C, Widen E, Groop PH, Eriksson J. Insulin resistance, hypertension and microalbuminuria in patients with type II (non insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 642-647
13. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265: 808-811.
14. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991; 40: 1007-1012
15. Hirano T, Kashiwazaki K, Morimoto Y, Nagano S, Adachi, M. Albuminuria is directly associated with increased plasma PAI-1 and factor levels in NIDDM patients. Diabetes Res Clin Pract 1997; 36: 11-18
16. Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Kitamura T, Ogawa W, Yokoyama M. TNF-α induces protein synthesis through PI3-kinase-Akt/PKB pathway in cardiac myocytes. Am J Physiol Heart Circ Physiol 2001; 280: H1861-1868
17. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000; 24 (Suppl 4): S23-27
18. Itoh Y, Yasui T, Kakizawa H, Makino M, Fujisawa K, Kato T, Imamura S, Yamamoto K, Hishida H, Nakai A, Itoh M, Nagasaka A. The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors. Prostaglandins Other Lipid Mediat 2001; 66: 221-234
19. Iwata M, Haruta T, Usui I et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-γ. Diabetes 2001; 50: 1083-1092
20. Katsuki A, Sumida Y, Murata K, Furuta M, Araki-Sasaki R, Tsuchihashi K, Hori Y, Yano Y, Gabazza EC, Adachi Y. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes Obes Metab 2000; 2: 189-191
21. Kreisberg JI, Ayo SH. The glomerular mesangium in diabetes mellitus. Kidney Int 1993; 43: 109-113
22. Kruithof EK. Plasminogen activator inhibitors - a review. Enzyme 1988; 40: 113-121.
23. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgett JR. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994; 369: 156-160
24. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-746
25. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Eng J Med 1993; 329: 1456-1462
26. Marino MW, Dunbar JD, Wu LW, Ngaiza JR, Han HM, Guo D, Matsushita M, Nairn AC, Zhang Y, Kolesnick R, Jaffe EA, Donner DB. Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine. J Biol Chem 1996; 271: 28,624-28,629
27. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Eng J Med 1996; 334: 939-945
28. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984; 74: 1143-1155
29. Meulders Q, He CJ, Adida C, Peraldi MN, Schuleuning WD, Sraer JD, Rondeau E. Tumor necrosis factor α increases antifibrinolytic activity of cultured human mesangial cells Kidney Int 1992, 42: 327-334
30. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor-α and insulin resistance in obese men with Type 2 diabetes mellitus. Diabetes Res Clin Pract 2001; 52: 119-123
31. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993; 42: 450-456
32. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA. Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hypertension 2001; 37: 722-727
33. Ninomiya Y, Arakawa M. Renal effects of prostaglandin E1 in type 2 (non-insulin-dependent) diabetic patients with subclinical nephropathy. Diabetes Res 1989; 10: 129-134
34. Niskanen L, Laakso M. Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus. Metabolism 1993; 42: 1541-1545
35. Parving HH, Osterby R, Anderson PW, Hsueh WA. In: Brenner BM (ed). Brenner and Rector's The Kidney. 5th ed. Philadelphia: W. B. Saunders, 1996: 1864-1883
36. Peraldi MN, Rondeau E, Medcalf RL, Hagege J, Lacave R, Delarue F, Schleuning WD, Sraer JD. Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells. Biochim Biophys Acta 1992; 1134: 189-196
37. Rerolle JP, Hertig A, Nguyen G et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000; 58: 1841-1850
38. Pirart J. Why don't we teach and treat diabetic patients better? Diabetes Care 1978; 1: 139-140
39. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T, Nebreda AR. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994; 78: 1027-1037
40. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35-65
41. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988; 4: 93
42. Sraer JD, Kanfer A, Rondeau E, Lacave R. Glomerular hemostasis in normal and pathologic conditions. Adv Nephrol Necker Hosp 1988; 17: 27-55
43. Suzuki M, Kanazawa A, Shiba M, Kojima H, Harano Y. Insulin resistance in diabetic microangiopathies. J Diabetes Complications 2000; 14: 40-45
44. Takata M, Urakaze M, Temaru R, Yamazaki K, Nakamura N, Nobata Y, Kishida M, Sato A, Kobayashi M. Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase. Br J Pharmcol 2001; 134: 753-762
45. Temaru R, Urakaze M, Sato A, Yamazaki K, Nakamura N, Kobayashi M. High glucose enhances the gene expression of interleukin-8 in human endothelial cells, but not in smooth muscle cells: possible role of interleukin-8 in diabetic macroangiopathy. Diabetologia 1997; 40: 610-613
46. Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992; 42: 1462-1469
47. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993; 9: 317-343
48. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-1072
49. Wahab NA, Mason RM. Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture. Biochem J 1996; 320: 777-783
50. Werb Z, Mainardi CL, Vater BA, Harris ED Jr. Endogenous activation of latent collagenase by rheumatoid synovial cells. N Engl J Med 1977; 296: 1017-1023
51. Wirta OR, Pasternack AI, Mustonen JT, Koivula TA, Harmoinen A. Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients. Nephrol Dial Transplant 1996; 11: 449-456